Astorg, EQT, New Mountain Capital and TA Associates are among the PE firms buying and selling active pharmaceutical ingredient assets.

ESTEVE CDMO, a global CDMO specializing in high-quality small-molecule APIs and pharmaceutical intermediates, began a $15.5 ...

QINGDAO, CHINA, January 19, 2026 /EINPresswire.com/ — As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened ...

Outsource API manufacturing to India for lower costs, GMP-compliant quality, scalable production, and faster time-to-market for pharma companies.

AbbVie’s $100 billion splurge on domestic manufacturing and R&D is continuing to come into focus, this time with a $380 million investment in two new active pharmaceutical ingredient manufactur | The ...

With a substantial manufacturing base already locked down in China, CRDMO BioDuro is taking a short jaunt down to Taiwan for its latest drug ingredients production play.  | BioDuro, headquartered in ...

DUBLIN, May 10, 2021 /PRNewswire/ -- The "Global Active Pharmaceutical Ingredient Market (2020-2025) by Type, Molecule, Product Type, Formulation Type, Manufacturing Type, Synthesis Type, Drug Type, ...

AbbVie invests $380 million to build two new API manufacturing facilities in North Chicago while Bora Pharmaceuticals Co., Ltd. and GSK have renewed a five-year global manufacturing partnership.

SHANGHAI, March 2, 2026 /PRNewswire/ -- CPHI & PMEC China 2026 is set to take place from 16 to 18 June 2026 at the Shanghai New International Expo Centre (SNIEC), building on its extremely successful ...

For decades, Africa has consumed medicines it did not manufacture. Across much of the continent, between 70 and 90 percent of ...